Innovations to reduce health inequalities
A research company focused on improving the health of sickle cell patients
Sickle cell disease is the most prevalent genetic disease worldwide. Even though it was discovered at the beginning of the 20th century, it is still a:
GLOBAL PUBLIC HEALTH ISSUE
5 million people affected
30 year reduction in life expectancy
Debilitating disease
SIGNIFICANT BURDEN
High social impact
High clinical costs
HIGH UNMET MEDICAL NEED
Lack of treatments
Poor utility of standard-of-care
Lack of diagnostic tools
OUR UNIQUE POSITIONING :
CHANGE THE PARADIGM OF SICKLE CELL MEDICAL CARE
Our solutions
Innovative biomarkers and clinical algorithms
TO ASSESS THE EFFICACY OF TREATMENTS
TO GUIDE PHYSICIANS TO PERSONALIZE TREATMENTS
Innovations
Biomarkers
Our biomarkers, specifically tailored to the pathophysiology of the disease, provide valuable insight to accurately assess treatment efficacy.
Single cell quantification of fetal hemoglobin
Intravascular hemolysis biomarkers
Single-cell HbF quantification
Intravascular hemolysis
CLINICAL ALGORITHMS
Unique predictive clinical scores combining a set of biomarkers and machine learning:
PREDICT TO AVOID
RESEARCH PROGRAMS
Validation of the first clinical algorithm to predict painful crises
Identification of the determinants of organ damage
Our solutions for…
PATIENTS
to better understand
your disease
CLINICAL PROVIDERS
to better follow-up
and treat your patients
PHARMA / BIOTECH
to support the development
of new therapies
Research services
A platform of unique biological assays to meet the needs of pharma and biotech companies, in terms of validation of clinical claims, with expert innovations.
News
Innovhem will present new data at the 2024 ASH Annual Meeting
Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new...
Innovhem’s patents have been issued !
Innovhem's patents protect our BIOMARKERS : An important news ! SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France,...
Innovhem paticipates to HEMOPROVE study, sponsored by AP-HP
HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will...
